Testing two antibiotics combined for serious bacterial infections
Part of Infections clinical trials.
This study tests whether combining two antibiotics (ceftazidime and fosfomycin) works better than ceftazidime alone for hospitalized adults with serious bacterial infections. If you have a severe infection thought to be caused by Gram-negative bacteria, this trial may offer a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are in the hospital with a severe infection likely caused by Gram-negative bacteria
- You are not pregnant or breastfeeding
- You do not have a known allergy to ceftazidime or fosfomycin
- You have not started antibiotics for this infection more than 24 hours ago
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well two antibiotics, ceftazidime-avibactam and fosfomycin, work together to treat infections caused by highly resistant bacteria called CRE. It may help find the best way to use these medicines.
This study is looking at how well two strong antibiotics (ceftazidime/avibactam and cefiderocol) work, with or without another drug called fosfomycin, for treating tough Gram-negative infections. It aims to help doctors understand the best way to use these medicines.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This trial tests whether giving the antibiotic ceftazidime-avibactam continuously or intermittently works better for ICU patients with severe infections caused by drug-resistant bacteria. The goal is to see which method improves outcomes.
This study tests a precise dosing approach for the antibiotic ceftazidime-avibactam to treat serious infections in ICU patients. It aims to help people with hard-to-treat bacteria that are resistant to many other antibiotics.
Hear when a new Gram Negative Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.